Apogee Therapeutics annual return on equity
2023
2024
2025
Apogee Therapeutics Return on Equity (ROE) Growth & History (APGE)
Apogee Therapeutics's return on equity was −31.57% for fiscal 2025.
View full Apogee Therapeutics company overviewApogee Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −31.57% | +1.64 pp |
| 2024 | 2024-12-31 | −33.22% | +11.00 pp |
| 2023 | 2023-12-31 | −44.21% | — |
Apogee Therapeutics quarterly return on equity
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −7.01% | +3.22 pp |
| Q1 2026 | 2026-03-31 | −6.86% | — |
| Q4 2025 | 2025-12-31 | −9.31% | — |
| Q3 2025 | 2025-09-30 | −10.79% | — |
| Q2 2025 | 2025-06-30 | −10.23% | — |
Apogee Therapeutics return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Apogee Therapeutics's return on equity increased from −44.21% to −31.57%, a change of +12.64 percentage points. The latest reported quarter, Q2 2026, shows −7.01%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Apogee Therapeutics source filings ↗